The cardiovascular activity of 2-amino-5-(3,4-dichlorophenoxymethyl)-2-oxazoline (APMO).
D000109:Acetylcholine / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003913:Dextroamphetamine / Q000494:pharmacology; D004285:Dogs; D004347:Drug Interactions; D005730:Ganglionic Blockers / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006584:Hexamethonium Compounds / Q000494:pharmacology; D006632:Histamine / Q000494:pharmacology; D007545:Isoproterenol / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010080:Oxazoles / Q000494:pharmacology*; D010643:Phenoxybenzamine / Q000494:pharmacology; D010647:Phenyl Ethers / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D012110:Reserpine / Q000494:pharmacology; D013116:Spinal Cord / Q000502:physiology; D014628:Vagotomy; D014630:Vagus Nerve / Q000502:physiology
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D005730:Ganglionic Blockers; D006584:Hexamethonium Compounds; D010080:Oxazoles; D010647:Phenyl Ethers; D010643:Phenoxybenzamine; C005974:APMO; D006632:Histamine; D012110:Reserpine; D011433:Propranolol; D007545:Isoproterenol; D000109:Acetylcholine; D003913:Dextroamphetamine; D009638:Norepinephrine